Hagen Schrötter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hagen Schrötter has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Katja Thomas
Center of Clinical Neuroscience, Department of Neurology, Carl Gustav Carus University Hospital, University of Technology Dresden, Fetscherstr. 74, 01307, Dresden, Germany
1 shared publication - Michael Halank
Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany
1 shared publication - Tjalf Ziemssen
Universitätsklinikum Carl Gustav Carus
1 shared publication
Latest Publications
- Open Access
- 7 June 2014
- Published by Springer Nature in BMC Neurology
- Vol. 14 (1) , 126
Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease
Fingolimod is the first oral immunomodulatory therapy approved for highly active relapsing remitting multiple sclerosis. Based on the distribution pattern of fingolimod interacting sphingosine-1-phosphat receptors in organism including immune system and cardiovascular system clinical monitoring of patients and evaluation of adverse events are recommended. Despite extensive data on cardiovascular safety, experience with fingolimod in patients with concomitant cardiological disease, especially within the pulmonary circulation, is rare.
- 7 June 2014
- Published by Springer Nature in BMC Neurology
- Vol. 14 (1) , 126
Open AccessFingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease
Fingolimod is the first oral immunomodulatory therapy approved for highly active relapsing remitting multiple sclerosis. Based on the distribution pattern of fingolimod interacting sphingosine-1-phosphat receptors in organism including immune system and cardiovascular system clinical monitoring of patients and evaluation of adverse events are recommended. Despite extensive data on cardiovascular safety, experience with fingolimod in patients with concomitant cardiological disease, especially within the pulmonary circulation, is rare.